Medicines for Europe, the trade association representing generic and biosimilar medicines manufacturers, today proposed five targeted patent reforms aimed at curbing the abuse of divisional patent applications in the pharmaceutical sector. The proposals, published on April 12, 2026, seek to prevent originator companies from using divisional patents to artificially extend market exclusivity and delay the entry of generic and biosimilar competitors.
The association's recommendations include limiting the filing of divisional applications to genuine technical divisions, introducing stricter examination timelines, increasing transparency of patent filings, and establishing a centralized EU patent opposition mechanism. These measures are designed to address what Medicines for Europe describes as a 'systemic abuse' of the divisional patent system, which it argues undermines timely patient access to affordable medicines.
The proposals come amid broader EU regulatory activity on pharmaceutical and veterinary medicines. On April 8, 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) proposed stricter requirements for pediatric medicine development, imposing more rigorous clinical trial standards and data requirements. The same day, EMA's Veterinary Medicines Division published a proposal for an enhanced monitoring framework for veterinary medicine effectiveness, targeting veterinary pharmaceutical companies with new reporting obligations. Additionally, EMA launched a series of awareness campaigns on veterinary medicine safety, including a 2026 awareness poster and a campaign to boost package leaflet awareness.
Medicines for Europe's reform proposals target the European Commission and EU member states, urging legislative action to close loopholes in the current patent framework. The association argues that divisional patent strategies, where multiple patents are filed from a single parent application, create legal uncertainty and increase litigation costs for generic manufacturers. The proposed reforms would impact pharmaceutical originator companies, generic and biosimilar manufacturers, national patent offices, and ultimately patients and healthcare systems by potentially accelerating market access for lower-cost medicines.
The initiative reflects ongoing tensions between innovation incentives for originator companies and the need for timely generic competition. While stronger patent protections encourage research and development, they can also delay market entry of cheaper alternatives, increasing healthcare costs. The proposals aim to strike a balance by targeting procedural abuses without undermining legitimate patent protection for genuine innovations.